Últimas noticias sobre DevvStream (NASDAQ:DEVS) Bolsa

DevvStream

DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

DevvStream Corp

JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) with a Market Outperform and maintains $20 price target.

News

Price Target

Reiteration

Analyst Ratings

TERN

JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $20 Price Target

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Outperform and lowers the price target from $28 to $26.

Keefe, Bruyette & Woods Maintains Outperform on Regions Finl, Lowers Price Target to $26

JMP Securities analyst Aaron Hecht reiterates Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Market Outperform and lowers the price target from $150 to $140.

JMP Securities Reiterates Market Outperform on Sun Communities, Lowers Price Target to $140

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Underperform and lowers the price target from $220 to $215.

Keefe, Bruyette & Woods Maintains Underperform on Marsh & McLennan Cos, Lowers Price Target to $215

Keefe, Bruyette &amp; Woods analyst David Konrad maintains KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Outperform and lowers the price target from $20 to $18.

Keefe, Bruyette & Woods Maintains Outperform on KeyCorp, Lowers Price Target to $18

Gold surged to fresh all-time highs on Monday, with bullion jumping 2.5% to $3,410 per ounce by 11:20 a.m. ET, as mounting distrust in U.S. financial assets and inflation fears drive a flight to safety unlike anything seen since the global debt crises <a href="https://www.benzinga.com/topic/donald-trump">of the early 2010s.</a>
Since early March, gold prices — tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) — have climbed an astonishing 19.4%, putting the metal on track for its strongest two-month rally since August 2011.
A perfect storm of macro instability, political friction and investor skepticism about the dollar and U.S. Treasuries is fueling the run.
<h1 class="wp-block-heading">What's Behind The Gold Boom?</h1>
The root of gold's dramatic resurgence lies in a potent mix of fundamental, structural and behavioral drivers.
The U.S. dollar and long-duration Treasuries — once go-to safe havens — have come under pressure in recent weeks amid President Donald Trump's tariff offensive and his escalating feud with Fed Chair Jerome Powell, raising fears over political interference and eroding confidence in U.S. institutions.
In this climate, gold's reputation as a neutral, time-tested store of value is attracting capital seeking stability.
As a result, traditional hedges have faltered. But gold, immune to sovereign missteps and backed by centuries of store-of-value status, has emerged as a refuge for capital looking for shelter from rising macro uncertainty.
Read also: <a href="https://www.benzinga.com/government/regulations/25/04/44899280/are-investors-selling-us-treasuries-as-trump-attacks-powell-heres-what-latest-etf-flows-tell-you">Are Investors Selling US Treasuries As Trump Attacks Powell? Here&#8217;s What Latest ETF Flows Tell You</a>
<h1 class="wp-block-heading">Massive Inflows Into Gold ETFs Confirm Strong Investment Demand</h1>
Investor appetite for gold is clearly visible in the massive inflows into gold-backed exchange-traded funds (ETFs) since mid-January, when Trump made his official return to the White House:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF Name </th>
<th>Inflows (Mid-January to Mid-April)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>)</td>
<td>$8.35 billion</td>
</tr>
<tr>
<td>iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>)</td>
<td>$3.5 billion</td>
</tr>
<tr>
<td>SPDR Gold MiniShares Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLDM#NYSE">GLDM</a>)</td>
<td>$2.46 billion</td>
</tr>
<tr>
<td>ProShares Ultra Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGL#NYSE">UGL</a>)</td>
<td>$117 million</td>
</tr>
<tr>
<td>Goldman Sachs Physical Gold ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAAU#NYSE">AAAU</a>)</td>
<td>$304.9 million</td>
</tr>
</tbody>
</table>
</figure>
These blockbuster flows signal broad-based institutional and retail demand. According to Goldman Sachs analyst Lina Thomas, the rally is not being fueled by short-term speculators.
"Data suggests the move has occurred without a substantial return of speculative flows," Thomas said. 
"With estimated COMEX speculative positioning still moderate, we view the rally as structurally supported and less exposed to sharp near-term liquidation risk. Thus, we see current levels as a tactically attractive entry point… and believe this reinforces upside risk to our $3,700/toz year-end forecast."
Ed Yardeni, president of Yardeni Research, said the current momentum validates his call from over a year ago. 
"We&#8217;ve been bullish on gold since it broke out above $2,000 per ounce at the end of February 2024. Our $4,000 target by the end of this year looks increasingly realistic. If that happens, then $5,000 would be our target for the end of 2026."
"This situation may come as a crisis for many assets, but for gold, it's a perfect outcome. Inflation fears remain high as the U.S. stock market loses trillions of dollars, and investors are leaning toward physical gold in search of security rather than risky assets like stocks and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)," said Rick Kanda, managing director at The Gold Bullion Company, in an email.
<h1 class="wp-block-heading">Miners Regain Momentum</h1>
The rally is also lifting gold miners, many of which had lagged physical bullion for much of 2024. Now, they're catching up. "Gold has surged to new all-time highs above $3,000/ounce, driven by renewed flows into gold-backed ETFs and continued strong demand from global central banks," VanEck said Monday.
"At the same time, gold miners are beginning to regain leverage to gold prices, emerging as some of the best-performing stocks so far this year."
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) is up nearly 52% year-to-date, eyeing the strongest annual gain since the fund&#8217;s inception in 2007.
In response to the metal's powerful rally, Bank of America on Monday raised price targets across its North American gold and silver coverage. 
The move comes just ahead of first-quarter earnings season in the precious metals sector, which begins April 23 with Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) and continues with Agnico Eagle Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) on April 24.
Here are the new price targets for key names:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>New Target</th>
<th>Previous Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agnico Eagle Mines </td>
<td>$159</td>
<td>$142</td>
</tr>
<tr>
<td>Barrick Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>)</td>
<td>$23</td>
<td>$19.50</td>
</tr>
<tr>
<td>Kinross Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>)</td>
<td>$17.50</td>
<td>$15</td>
</tr>
<tr>
<td>Newmont Corp. </td>
<td>$70</td>
<td>$60</td>
</tr>
<tr>
<td>B2Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTG#NYSE">BTG</a>)</td>
<td>$3.10</td>
<td>$2.75</td>
</tr>
<tr>
<td>Centerra Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGAU#NYSE">CGAU</a>)</td>
<td>$6.50</td>
<td>$5.50</td>
</tr>
<tr>
<td>Eldorado Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGO#NYSE">EGO</a>)</td>
<td>$19.50</td>
<td>$17.25</td>
</tr>
<tr>
<td>IAMGOLD Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>)</td>
<td>$9.25</td>
<td>$7.75</td>
</tr>
<tr>
<td>SSR Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>)</td>
<td>$9.75</td>
<td>$8.50</td>
</tr>
<tr>
<td>Alamos Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>)</td>
<td>$35</td>
<td>$30.50</td>
</tr>
<tr>
<td>New Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGD#NYSE">NGD</a>)</td>
<td>$4.55</td>
<td>$4.10</td>
</tr>
<tr>
<td>Pan American Silver Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NASDAQ">PAAS</a>)</td>
<td>$32</td>
<td>$27</td>
</tr>
<tr>
<td>Franco-Nevada Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>)</td>
<td>$195</td>
<td>$165</td>
</tr>
<tr>
<td>Royal Gold Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>)</td>
<td>$183</td>
<td>$164</td>
</tr>
<tr>
<td>Triple Flag Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#NYSE">TFPM</a>)</td>
<td>$27</td>
<td>$24</td>
</tr>
<tr>
<td>Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>)</td>
<td>$100</td>
<td>$86</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44886209/if-you-had-bet-on-gold-after-the-1971-nixon-shock-youd-have-beaten-the-sp-500-unless-you-did-this-one-thing">If You Had Bet On Gold After The 1971 Nixon Shock, You&#8217;d Have Beaten The S&amp;P 500 — Unless You Did This One Thing</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AAAU

CGAU

Market Vectors ETF Trust Market Vectors Gold Miners

GLDM

GOLD

PAAS

RGLD

SSRM

TFPM

Gold Price Soars To Record Highs, Eyes Best 2-Month Rally Since 2011 On Blockbuster ETF Buying

JMP Securities analyst Devin Ryan reiterates Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Market Outperform and maintains $94 price target.

SCHW

JMP Securities Reiterates Market Outperform on Charles Schwab, Maintains $94 Price Target

On Friday, the Food and Drug Administration updated the U.S. Prescribing Information for Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos (mavacamten), simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">by reducing contraindications</a>.
Camzyos is the first and only FDA-approved cardiac myosin inhibitor for adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44880541/u-s-food-and-drug-administration-updates-camzyos-mavacamten-label-to-reduce-echocardiography-monit" rel="noreferrer noopener">capacity and symptoms</a>.
FDA-approved updates include reduced frequency of required echo monitoring from once every 12 weeks to every 6 months for patients with left ventricular ejection fraction (LVEF) ≥55% and a Valsalva left ventricular outflow tract (LVOT) gradient &lt;30 mmHg (or Valsalva LVOT ≥30 mmHg without up-titration) who have reached the maintenance phase (at Week 12 or later).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44715789/fda-approves-bristol-myers-opdivo-plus-yervoy-combo-for-untreated-colorectal-cancer-patients" rel="noreferrer noopener">FDA Approves Bristol Myers&#8217; Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients</a>
Additionally, Camzyos is no longer contraindicated with moderate CYP2C19 and strong CYP3A4 inhibitors, which were adjusted to drug interactions.
The approved label update is supported by long-term clinical and real-world data, including analyses of results from the Camzyos Risk Evaluation and Mitigation Strategy (REMS) Program, real-world experience from three single-center studies, and ongoing clinical data reinforcing Camzyos&#8217;s safety profile over the past 3.5 years.
William Bliar analyst Matt Phipps writes the update is largely in line with that hinted by management and supported by real-world evidence, which will reduce the burden for physicians managing patients on Camzyos.
Phipps also views the update as timely ahead of the assumed approval of Cytokinetic Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) aficamten, with a PDUFA date of September 26.
The analyst says they are now waiting for details on the monitoring requirements for aficamten to determine potential areas of differentiation and how this may impact new market share in the coming years, assuming approval on September 26.
Last week, Bristol Myers Squibb announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos&nbsp;(mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44825297/why-us-pharma-giant-bristol-myers-squibb-stock-trading-lower-on-tuesday" rel="noreferrer noopener">hypertrophic cardiomyopathy (nHCM)</a>.
The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44801468/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial" rel="noreferrer noopener">consumption (pVO2)</a>.
No new safety signals were observed.
Price Action: BMY stock was down 0.7% at $48.83 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44895667/alibabas-ai-powered-cancer-detection-tool-wins-fda-breakthrough-status" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s AI-Powered Cancer Detection Tool Wins FDA Breakthrough Status</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Health Care

General

CYTK

Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach

Keefe, Bruyette &amp; Woods analyst Christopher O'Connell maintains Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) with a Market Perform and lowers the price target from $80 to $72.

INDB

Keefe, Bruyette & Woods Maintains Market Perform on Independent Bank, Lowers Price Target to $72

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Market Perform and lowers the price target from $18 to $17.

HBAN

Keefe, Bruyette & Woods Maintains Market Perform on Huntington Bancshares, Lowers Price Target to $17

JMP Securities analyst Nicholas Jones reiterates Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Market Outperform and maintains $24 price target.

GRND

JMP Securities Reiterates Market Outperform on Grindr, Maintains $24 Price Target

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Great Southern Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) with a Market Perform and lowers the price target from $63 to $61.

GSBC

Keefe, Bruyette & Woods Maintains Market Perform on Great Southern Bancorp, Lowers Price Target to $61

JMP Securities analyst Patrick Walravens maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Market Outperform and maintains $124 price target.

DOCU

JMP Securities Maintains Market Outperform on Docusign, Maintains $124 Price Target

Trading Ideas

Live On CNBC, Amy Raskin Announces bought More Franco-Nevada

WIIM

Nike shares are trading lower after Williams Trading cut its price target on the stock from $93 to $73.

JMP Securities analyst Aaron Hecht maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Market Outperform and lowers the price target from $210 to $180.

JMP Securities Maintains Market Outperform on D.R. Horton, Lowers Price Target to $180

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Bar Harbor Bankshares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BHB#AMEX">BHB</a>) with a Market Perform and lowers the price target from $35 to $33.

Keefe, Bruyette & Woods Maintains Market Perform on Bar Harbor Bankshares, Lowers Price Target to $33

ServiceNow shares are trading lower after Barclays cut its price target on the stock from $1200 to $967.

JMP Securities analyst Steven Delaney reiterates Ares Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRE#NYSE">ACRE</a>) from Market Perform to Market Perform.

ACRE

JMP Securities Reiterates Market Perform on Ares Comml Real Estto Market Perform

Truist Securities analyst David Macdonald maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Buy and lowers the price target from $660 to $580.

Truist Securities Maintains Buy on UnitedHealth Group, Lowers Price Target to $580

Press Releases

SEER PARTNERS WITH DEVVSTREAM TO MONETIZE INSURED CARBON CREDITS ARISING OUT OF METHANE RENEWABLE ENERGY, CAPTURED OIL FIELD WELL EMISSIONS AND OTHER SEER PROJECTS

SENR

Comments

DevvStream

Noticias

Últimas noticias sobre DevvStream (NASDAQ:DEVS) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL